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From The 4th Meeting of the Core Outcome Measures in Effectiveness Trials (COMET) Initiative Rome, Italy. 19-20 November 2014 Background Except for studies where composite outcomes are chosen, a randomized controlled trial must have a primary outcome parameter. The primary outcome must be unambiguous, reliably assessable and clinically relevant. The estimated difference between the primary outcome in the study and control group(s) is used for the power calculation to determine the number of subjects needed for the trial.
Methods
We reviewed all RCTs published in three urogynecology journals (International Urogynecology Journal -IUJ), Neurourology and Urodynamics -NAU, Female Pelvic Medicine and Reconstructive Surgery -FPMRS) and three general gynecology journals (Obstetrics and Gynecology -GREEN, American Journal of Obstetrics and Gynecology -AJOG, and BJOGan International Journal of Obstetrics and Gynecology) in the field of Urogynecology in the year 2013.
The journals were hand searched for clinical randomized controlled trials, and the following variables were noted: type of primary outcome, number of secondary outcomes, power calculation.
Results
After excluding secondary analyses, a total of 34 randomized controlled trials were identified in the 6 journals in 2013 (IUJ 19, NAU 5, FPMRS 3, GREEN 6, AJOG 0, BJOG 1). 3/34 papers listed more than one primary outcome, while 8/34 papers did not list any secondary outcomes (Table 1) .
The most common primary outcomes chosen by the investigators were results of questionnaires (n=8), and POPQ (pelvic organ prolapse quantification system) statements and bladder diaries (5 each).
Correct power calculations were done in 25/34 studies, and in 3 studies power calculation were reported in the methods section without giving the variable on which the power calculation was performed. 
